PhD in Biology from the University of Granada (1994), awarded with distinction. Professor of Cell Biology in the Department of Experimental Biology at the University of Jaén. I am part of the research group RNM924 “Human and Animal Molecular Genetics” of the Andalusian Plan for R&D&I (https://web.ujaen.es/investiga/cvi220/). My research focuses on the analysis of molecules involved in immune tolerance in celiac disease, developing in vitro study models. In collaboration with the company Biomedal, we have utilized the monoclonal antibody G12 as an indicator of reactivity or non-reactivity in various barley and oat varieties, allowing us to identify and quantify the most toxic fractions in different varieties. Additionally, we have conducted assays to neutralize the immunotoxicity of hydrolyzed foods using anti-gliadin antibodies, obtaining antibodies for conjugation to chromatographic resins.
IMPORTANT – The Curriculum Vitae cannot exceed 4 pages. Instructions to fill this document are available in the website.
CURRICULUM VITAE ABREVIADO (CVA)
The goal is to capture hydrolyzed peptides with these columns, evaluate their ability to activate T cells in celiac patients, sequence them, and determine which peptides are retained by the antibodies, while comparing the most immunostimulatory peptides. We have developed RNA interference (RNAi) as an optimal approach to downregulate genes encoding immunogenic proteins related to celiac disease, providing an alternative for the development of cereals suitable for celiac patients. All these experiments have been published in prestigious journals such as GUT, Molecular Nutrition & Food Research, Food Chemistry, Frontiers in Immunology, Cellular & Molecular Immunology, and Nutrients.
I have published 86 articles in international journals and 9 book chapters. I have participated in numerous research projects, all obtained through competitive national and regional calls, and with companies such as Abbott. I am currently part of the Andalusian Platform for Biomodels and Resources in Genomic Editing with Biotechnology Applied to Health (BAS), whose main objective is the implementation of pioneering and unique biotechnological platforms focused on developing tools for diagnosis and advanced or specific therapies in personalized medicine. The aim is to integrate these platforms into routine processes for research and decision-making (diagnosis, prognosis, treatment of diseases), providing a competitive and innovative advantage.
Human Intestinal Organoids Chip technology to model celiac disease functionality
López Casado Miguel Ángel1, Torres López María Isabel2
1Department of Pediatrics Gastroenterology, Hospital Virgen de las Nieves, Granada, Spain.
2Department of Experimental Biology, University of Jaén, Jaén, Spain.
The Human Intestinal Organoids Chip technology is a cutting-edge platform designed to model the human intestine's functionality, offering insights into diseases such as celiac disease, where the immune system reacts abnormally to gluten. Organoids are three-dimensional cell cultures derived from stem cells that self-organize into structures mimicking specific organs. For the intestine, organoids closely replicate the epithelial lining and cellular diversity of the human gut, making them powerful tools for studying diseases like celiac disease. This microfluid chip designed to house multiple cell types in a dynamic environment including the epithelial layer, the lamina propria (containing immune cells), and the underlying extracellular matrix, that replicate nutrient absorption and secretion of digestive enzymes. Organoids are derived from patient-specific cells, offering an opportunity to model each individual's unique intestinal biology. These organoids mimic the structure and cellular composition of the human gut. By integrating intestinal organoids with organ-on-chip technology, we can create more advanced models that replicate both the cellular complexity of organoids and the dynamic, mechanical properties of the organ-on-chip, allowing for individualized disease study and treatment testing. The Intestinal Chip enables the study of the breakdown of the gut barrier, inflammation, immune activation and the presence of the microbiome in real-time, allowing for the study of how gut bacteria interact with intestinal cells and the immune system. The organ chip facilitates the delivery of gluten peptides and monitoring of their effects on intestinal cells, including how they trigger immune responses or damage villi, which are key elements of celiac pathology. Additionally, it provides an opportunity to test potential therapies, such as gluten-degrading enzymes or immunosuppressants, under conditions that closely resemble the human gut.
Key words: Intestinal organoids, organ-on-chip technology, celiac disease
What will audience learn from my presentation?
• Explain how the audience will be able to use what they learn?
Clinicians and researchers will gain insight into how to tailor treatments to individual patients. Since organoids are derived from patient-specific cells, this technology supports the growing field of personalized medicine by allowing more accurate predictions of how a particular patient might respond to treatments.
• How will this help the audience in their job?
This technology bridges the gap between basic research and clinical application, enabling scientists and healthcare providers to simulate patient-specific intestinal conditions and test interventions with unprecedented precision and relevance.
• Is this research that other faculty could use to expand their research or teaching?
Yes, the Human Intestinal Organoids on Chip Technology is highly applicable for expanding both research and teaching within academic settings, particularly in areas related to gastrointestinal diseases, microbiology, immunology, and biotechnology. This cutting-edge platform combines stem-cell-derived organoids with organ-on-chip technology, allowing faculty in various disciplines to use it in diverse ways.
• Does this provide a practical solution to a problem that could simplify or make a designer’s job more efficient?
Yes, Human Intestinal Organoids on Chip Technology enhances the precision, scalability, and speed of experiments, reducing labor-intensive processes and offering designers more efficient tools to model disease and test therapies in human-relevant conditions.
• Will it improve the accuracy of a design, or provide new information to assist in a design problem?
Human Intestinal Organoid Chip technology contributes both to improving the accuracy of biological models and to offering new insights that solve design problems in drug development and disease treatment. Its ability to replicate human-specific responses, combined with the personalized data it can provide, makes it an invaluable tool in the evolving landscape of biomedical research and therapy design.
• List all other benefits.
Human Intestinal Organoid Chip technology improved physiological accuracy, enhanced disease modeling, offfer personalized medicine, allows microbiome interaction studies, provide drug development and testing, ensure resproducibility and scalability and compatibilize with advanced imaging and monitoring
